Subscribe
igor-stevanovic-shutterstock-com
igor.stevanovic / Shutterstock.com
28 May 2015Americas

Acorda hits back at Kyle Bass IPR

Acorda Therapeutics, the first company to be targeted through an inter partes review (IPR) filed by US hedge fund manager Kyle Bass, has asked the US Patent and Trademark Office (USPTO) to reject the petition.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
PTAB gives green light to four Acorda IPR trials
16 March 2016   The Patent Trial and Appeal Board has instituted trials on four patents owned by Acorda Therapeutics following challenges from the Coalition for Affordable Drugs and hedge fund manager Kyle Bass.
Americas
Hedge fund manager defends IPR petitions
13 April 2015   Dallas-based hedge fund Hayman Capital Management has defended its owner’s decision to challenge a clutch of patents using the inter partes review procedure.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
PTAB gives green light to four Acorda IPR trials
16 March 2016   The Patent Trial and Appeal Board has instituted trials on four patents owned by Acorda Therapeutics following challenges from the Coalition for Affordable Drugs and hedge fund manager Kyle Bass.
Americas
Hedge fund manager defends IPR petitions
13 April 2015   Dallas-based hedge fund Hayman Capital Management has defended its owner’s decision to challenge a clutch of patents using the inter partes review procedure.

More on this story

Americas
PTAB gives green light to four Acorda IPR trials
16 March 2016   The Patent Trial and Appeal Board has instituted trials on four patents owned by Acorda Therapeutics following challenges from the Coalition for Affordable Drugs and hedge fund manager Kyle Bass.
Americas
Hedge fund manager defends IPR petitions
13 April 2015   Dallas-based hedge fund Hayman Capital Management has defended its owner’s decision to challenge a clutch of patents using the inter partes review procedure.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB